The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
about
Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damageChaperoning steroid hormone signaling via reversible acetylation.Different Poses for Ligand and Chaperone in Inhibitor-Bound Hsp90 and GRP94: Implications for Paralog-Specific Drug DesignNovel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformationClient Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted MutantsMisfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.Hsp90 inhibition decreases mitochondrial protein turnover.Anti-leukemia activity of a Hsp70 inhibitor and its hybrid moleculesDestabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)Caspase-dependent, geldanamycin-enhanced cleavage of co-chaperone p23 in leukemic apoptosis.Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cellsResistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140.Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.Heat shock proteins as emerging therapeutic targets.Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugsDiscovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?Heat shock proteins and acute leukemias.Targeting the ubiquitin-proteasome pathway in breast cancer therapy.Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Current status of agents active against the T315I chronic myeloid leukemia phenotype.Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.A cell-based screen for inhibitors of protein folding and degradation.Sensitization of K562 Leukemia Cells to Doxorubicin by the Viscum album Extract.The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection.Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia.Do cells need CDK2 and ... Bcr-Abl?Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention.A proteomic approach to identifying new drug targets (potentiating topoisomerase II poisons).
P2860
Q25257535-FD72FEDE-28A3-4918-A932-2B73533DD29CQ25257831-9C95039E-675A-4DA5-B93B-3D53D505A88BQ27654646-FDC7829A-7D7E-4433-8A0E-C49B23AE290DQ27824789-89074992-1FD4-443E-9233-6037C1863335Q28238796-C9471ADD-61CA-42A5-AFD6-03AEA10643B7Q28550576-5F8403D6-F6CC-4A35-B186-E789507D00F0Q30374671-69DA1D42-DBB9-4251-8E3B-F3E6348A1080Q33303676-4C91CB71-64CB-4FE4-B700-17CEAA258B45Q33799516-08F01940-CAB8-4FE3-BFDF-E286B22EAE95Q34082540-6DF9A985-803F-4945-9E74-5CAE3D651032Q34358774-7AE21956-023C-43CA-B148-27412EC0C400Q34483497-0CC09334-2883-4C29-9A0B-A53BBCF216A3Q35128883-C2F6972D-0CFC-46FA-B927-145E96EC1D1AQ35169884-FBBF9D6C-8D4B-44EF-AC12-E24059008E98Q35528633-70E4D381-742C-4680-92B7-06335C9CE19BQ35545091-43FC699B-0178-4F88-9EF9-31A423C963DCQ35823157-583EFA1B-BFF3-44DF-887C-3D7F70A764E3Q35828517-F36F2587-2F76-4878-97E1-117976D7E72BQ35847836-C292294E-F5E9-4D14-B4C8-2E6370C01A46Q36187025-20C1E72B-775E-4E2D-B931-9B0CEBFB3E06Q36194587-56709B1D-2981-4B03-8E6A-5B7397BB2BD0Q36429691-D0DA3B04-D778-4148-AC66-0AE3A59C3F61Q36544683-FA94F079-B778-4850-97FE-EAFDCBB56490Q37278393-A3B295C5-60F1-4CE1-AF1B-EB19B41CD0D7Q37728631-546315A9-5F1B-4F9C-8D9B-3D5ADC7A407DQ37827173-A5FA54F7-E4B7-46EF-9168-EE13DAF93E9EQ37847179-22FFFEC6-D8A5-4948-AAF1-8F6E9EBC5118Q39188679-4240B562-B943-4F3D-BE9D-82E9B854BD55Q39666425-64581D72-00D3-4C11-8AE5-67E880F36ED6Q40182949-BE17E708-4EE6-4BB3-BA26-207F625941FCQ40213329-EA572308-3587-4387-B5E1-4BB4ECA5E82CQ40346972-4B4B8F25-5003-4E66-B09A-14892D023086Q40468950-0F72E4CB-4AB0-466C-B633-737DC8B7FC16Q40635020-3367F7D2-4970-4EA4-8852-9F2B776FC4FBQ42110946-CFDA5DA6-ABE2-4E77-AEC8-F26CCACFB15FQ44529449-AED3C409-E6B1-4D77-9003-EF489DFD63F7Q44699399-C25D7AE9-E71D-4A50-903F-4EFDCE7FB878Q46368537-A68D61D9-2076-417E-BE91-40295206D3A2Q53448876-FB0D5109-EFD8-457A-9F4F-4EA554992C39
P2860
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@ast
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@en
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@nl
type
label
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@ast
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@en
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@nl
prefLabel
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@ast
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@en
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@nl
P2093
P921
P356
P1433
P1476
The Hsp90 inhibitor geldanamyc ...... lls to cytotoxic chemotherapy.
@en
P2093
Blagosklonny MV
Neckers LM
P2888
P304
P356
10.1038/SJ.LEU.2402257
P577
2001-10-01T00:00:00Z
P5875
P6179
1016393293